Table 2.
Treatment durations
| Denosumab (N = 3495) | Oral bisphosphonates (N = 13,134) | Intravenous ibandronate (N = 1801) | Intravenous zoledronate (N = 379) |
Teriparatide (N = 43) |
Raloxifene (N = 120) | HRT (N = 22,889) | |
|---|---|---|---|---|---|---|---|
| Median (IQR) treatment duration (days)a | |||||||
| Overall | 587 (701) | 258 (638) | 451 (683) | 389 (457) | 442 (559) | 160 (591) | 149 (269) |
| No prior treatment | 560 (817) | 259 (637) | 372 (689) | 358 (399) | 473 (559) | 160 (553) | 149 (265) |
| Prior treatment | 614 (709) | 234 (647) | 501 (727) | 559 (696) | 356 (385) | 84 (732) | 148 (341) |
aTreatment duration was measured as continuous treatment with index therapy until a gap of more than 60 days without filling a new prescription after the expected refill date or treatment switching occurred
HRT, hormone replacement therapy; IQR, interquartile range